Monitoring antimalarial drug efficacy: Current challenges

Current Infectious Disease Reports

Volumn 11, Issue 1, 2009, Pages 59-65

  Laufer, Miriam K ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ;

AGE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNE RESPONSE; MALARIA; OPPORTUNISTIC INFECTION; PARASITE TRANSMISSION; PARASITEMIA; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; RECURRENT INFECTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 65649145325     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0009-3     Document Type: Review

References (45)

1. World Health Organization: Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: World Health Organization; 2003.
2. Stepniewska K, Taylor WR, Mayxay M, et al.: In vivo assessment of drug efficacy against Plasmodium falciparum malaria: Duration of follow-up. Antimicrob Agents Chemother 2004, 48:4271-4280.
3. World Health Organization: Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva, Switzerland: World Health Organization; 2008.
4. Hoffman SL, Masbar S, Hussein PR, et al.: Absence of malaria mortality in villagers with chloroquine-resistant Plasmodium falciparum treated with chloroquine. Trans R Soc Trop Med Hyg 1984, 78:175-178.
5. Djimde AA, Doumbo OK, Traore O, et al.: Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003, 69:558-563.
6. Laufer MK, van Oosterhout JJ, Thesing PC, et al.: Malaria treatment efficacy among people living with HIV: The role of host and parasite factors. Am J Trop Med Hyg 2007, 77:627-632.
7. Greenhouse B, Slater M, Njama-Meya D, et al.: Decreasing efficacy of antimalarial combination therapy in Uganda explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis, in press.
8. Dzinjalamala FK, MacHeso A, Kublin JG, et al.: Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2005, 72:267-272.
9. Laufer MK, Plowe CV: The interaction between HIV and malaria in Africa. Curr Infect Dis Rep 2007, 9:47-54.
10. Laufer MK, van Oosterhout JJ, Thesing PC, et al.: Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 2006, 193:872-878.
11. Price RN, Uhlemann AC, van Vugt M, et al.: Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006, 42:1570-1577.
12. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet 1999, 37:105-125.
13. White NJ, Stepniewska K, Barnes K, et al.: Simplified antimalarial therapeutic monitoring: Using the day-7 drug level? Trends Parasitol 2008, 24:159-163.
14. World Health Organization: Containment of Malaria Multi-Drug Resistance on the Cambodia-Thailand Border. Geneva, Switzerland: World Health Organization; 2007. Report no. SEA-MAL-246.
15. Noedl H, Thap LC, Se Y, et al.: Artemisinin resistance in Cambodia? [abstract 934]. Presented at the Annual Meeting of the American Society of Tropical Medicine. Philadelphia, PA; November 8, 2007.
16. Ittarat W, Pickard AL, Rattanasinganchan P, et al.: Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg 2003, 68:147-152.
17. Laufer MK, Djimde AA, Plowe CV: Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg 2007, 77(6 Suupl):160-169.
18. Kaddouri H, Djimde A, Dama S, et al.: Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol 2008, 38:791-798.
19. Bacon DJ, Latour C, Lucas C, et al.: Comparison of a SYBR green I-based assay with a histidine-rich protein II enzymelinked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother 2007, 51:1172-1178.
20. Rason MA, Randriantsoa T, Andrianantenaina H, et al.: Performance and reliability of the SYBR green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg 2008, 102:346-351.
21. Basco LK: Molecular epidemiology of malaria in Cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am J Trop Med Hyg 2004, 70:474-480.
22. Bacon DJ, Jambou R, Fandeur T, et al.: World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility. Malar J 2007, 6:120.
23. Ekland EH, Fidock DA: In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol 2008, 38:743-747.
24. Bzik DJ, Li WB, Horii T, Inselburg J: Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci U S A 1987, 84:8360-8364.
25. Foote SJ, Thompson JK, Cowman AF, Kemp DJ: Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 1989, 57:921-930.
26. Brooks DR, Wang P, Read M, et al.: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 1994, 224:397-405.
27. Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 1988, 85:9114-9118.
28. Wellems TE, Walker-Jonah A, Panton LJ: Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci U S A 1991, 88:3382-3386.
29. Fidock DA, Nomura T, Talley AK, et al.: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000, 6:861-871.
30. Plowe CV, Cortese JF, Djimde A, et al.: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997, 176:1590-1596.
31. Wang P, Lee CS, Bayoumi R, et al.: Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 1997, 89:161-177.
32. Djimde A, Doumbo OK, Cortese JF, et al.: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001, 344:257-263.
33. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al.: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002, 185:380-388.
34. Djimde A, Doumbo OK, Steketee RW, Plowe CV: Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001, 358:890-891.
35. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al.: Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957-961.
36. Jambou R, Legrand E, Niang M, et al.: Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
37. Zhang G, Guan Y, Zheng B, et al.: No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China. Malar J 2008, 7:122.
38. Mugittu K, Genton B, Mshinda H, Beck HP: Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malar J 2006, 5:126.
39. Ferreira ID, Lopes D, Martinelli A, et al.: In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from Sao Tome and Principe. Trop Med Int Health 2007, 12:353-362.
40. Price RN, Uhlemann AC, Brockman A, et al.: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
41. Sidhu AB, Uhlemann AC, Valderramos SG, et al.: Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 2006, 194:528-535.
42. Ferreira ID, Rosario VE, Cravo PV: Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum. Malar J 2006, 5:1.
43. Nyunt MM, Plowe CV: Pharmacologic advances in the global control and treatment of malaria: Combination therapy and resistance. Clin Pharmacol Ther 2007, 82:601-605.
44. Stepniewska K, White NJ: Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008, 52:1589-1596.
45. Sibley CH, Barnes KI, Watkins WM, Plowe CV: A network to monitor antimalarial drug resistance: A plan for moving forward. Trends Parasitol 2008, 24:43-48.